Sepracor has promoted Adrian Adams, president and chief operating officer, to the role of president and CEO.
Cell Therapeutics announced the following appointments top the management team for its recently- formed subsidiary Aequus BioPharma: Carl J. March, Ph.D., MBA, has been named to lead the new company as president and CEO. Stewart D. Chipman, Ph.D., will serve as executive vice president and chief scientific officer; David Cosman, Ph.D., will join the company's board of directors.
Mark Faupel has been named as the new chief executive officer of SpectRx.
Fred Kurland joined Bayhill Therapeutics in the newly created position of chief financial officer.
Mersana Therapeutics has named Robert J. Fram, M.D., to the newly created position of chief medical officer.
Anthony F. Purchio, Ph.D. has joined Numira Biosciences as chief scientific officer.
Intrexon Corporation has named Costas Loullis, Ph.D. as the vice president of research and development.
Biogen Idec has named Lewis J. Klunk, Ph.D. vice president, drug metabolism and pharmacokinetics.
CellCyte Genetics has named Dr. Andreas Kalmes, Ph.D. to the position of vice president of pharmacology.
Neurobiological Technologies has named Vicki Higham, MSN, RN, as clinical project manager.
Judith Bryson has been named as the new vice president for clinical development at Serenex.
The Burnham Institute for Medical Research has recruited Elizabeth Gianini as vice president, external relations for Burnham at Lake Nona, Orlando.
SommaTech has added John W. Gotto, Ph.D. and D. Amanda Gotto, as senior consultants.
Chemokine Therapeutics announced that Dr. Anthony Tolcher has joined its oncology Clinical Advisory Board.
InNexus Biotechnology announced that Dr. Thomas Kindt has joined its newly formed Scientific Advisory Board.
ExonHit Therapeutics announced that Deborah Smeltzer has been appointed member of its Supervisory Board.
Thomas E. Gardner has been appointed to the Nucryst Pharmaceuticals' board of directors.
Achillion Pharmaceuticals has named Robert L. Van Nostrand to its board of directors.
IR BioSciences Holdings has appointed Lance K. Gordon, Ph.D. to its board of directors.
Professor Zhi-Xin Wang of the Department of Biological Sciences and Biotechnology at Beijing's Tsinghua University has joined SinoBiomed's board of directors.
Resverlogix has appointed Roger Newton, PhD, to the board.
ImClone Systems has named Jules Haimovitz to its board.